Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.53 |
| ▸ | NPY1R | P25929 | 2/20 | 0.52 |
| ▸ | NPY2R | P49146 | 2/20 | 0.52 |
| ▸ | NPY4R | P50391 | 2/20 | 0.52 |
| ▸ | ECE1 | P42892 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29924961 | 1.00 | ACE (0.55) | ACEERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL29924965 | 1.00 | ACE (0.55) | ACEERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL30389391 | 0.99 | ACE (0.54) | ACEERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL30462544 | 0.99 | ACE (0.54) | ACEERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL30389486 | 0.99 | ACE (0.54) | ACEERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL30389400 | 0.99 | ACE (0.54) | ACEERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL29837379 | 0.99 | ACE (0.54) | ACEERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL30646171 | 0.99 | ACE (0.54) | ACEERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL30945412 | 0.99 | ACE (0.54) | ACEERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL30388732 | 0.99 | ACE (0.54) | ACEERAP2ERAP1LNPEPNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106912-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4743080-A2 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026090245-A1 | USE OF RAS INHIBITORS FOR TREATING CANCER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090116-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090127-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108528-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | REVOLUTION MEDICINES INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12589160-B2 | Peptide-derived therapeutics targeting KDM5C for the treatment of cancer | NUVOBIO CORPORATION (CA) | 2026-03-31 | — | — | US | disclosed |
| US-20260078133-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2026-03-19 | — | — | US | disclosed |
| EP-4704850-A1 | COMBINATION THERAPY FOR A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4687905-A1 | COMPOSITIONS FOR INDUCING RAS GTP HYDROLYSIS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250049810-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. | 2025-02-13 | — | — | US | disclosed |
| US-20250041295-A1 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-02-06 | — | — | US | disclosed |
| WO-2025019318-A2 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024229406-A1 | COMBINATION THERAPY FOR A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024206858-A1 | COMPOSITIONS FOR INDUCING RAS GTP HYDROLYSIS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2024-10-03 | — | — | WO | disclosed |
| CN-118265536-A | Engineered antibacterial peptides and uses thereof | 肽逻辑公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20220289794-A1 | SYNTHETIC ANTIMICROBIAL PEPTIDES | AJK BIOPHARMACEUTICAL LLC (US) | 2022-09-15 | — | — | US | disclosed |
| WO-2022173981-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | PEPTILOGICS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20220184221-A1 | PEPTIDE-DERIVED THERAPEUTICS TARGETING KDM5C FOR THE TREATMENT OF CANCER | NUVOBIO CORPORATION (CA) | 2022-06-16 | — | — | US | disclosed |
| US-20220185844-A1 | PEPTIDE-DERIVED THERAPEUTICS TARGETING SET8 FOR THE TREATMENT OF CANCER | NUVOBIO CORPORATION (CA) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078133-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ACE 947/4885ERAP2 4250/4885ERAP1 3564/4885 |
| US-20250049810-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | KRAS, HRAS, NRAS | ACE 603/4885ERAP2 2261/4885ERAP1 2512/4885 |
| US-20220184221-A1 | PEPTIDE-DERIVED THERAPEUTICS TARGETING KDM5C FOR THE TREATMENT OF CANCER | KDM5C, KDM5B, KDM5A | ACE 3839/4885ERAP2 1899/4885ERAP1 786/4885 |
| US-20250041295-A1 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | KRAS, NRAS, HRAS | ACE 130/4885ERAP2 1571/4885ERAP1 2250/4885 |
| US-20220289794-A1 | SYNTHETIC ANTIMICROBIAL PEPTIDES | VIP, HM13, NGLY1 | ACE 2034/4885ERAP2 506/4885ERAP1 208/4885 |
| US-12589160-B2 | Peptide-derived therapeutics targeting KDM5C for the treatment of cancer | SUV39H1, SUV39H2, SMYD2 | ACE 4095/4885ERAP2 4109/4885ERAP1 2617/4885 |
| US-20220185844-A1 | PEPTIDE-DERIVED THERAPEUTICS TARGETING SET8 FOR THE TREATMENT OF CANCER | SETDB1, SETD7, SENP8 | ACE 4394/4885ERAP2 1660/4885ERAP1 965/4885 |
| US-20260108528-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | KRAS, NRAS, RAB1A | ACE 1898/4885ERAP2 4132/4885ERAP1 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.